Transcriptional Targeting of Dendritic Cells Using an Optimized Human

cytomegalovirus dendritic cell fascin1 gene delivery plasmid DNA polyethylenimine polyplex promotor activity tumor cell

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Nov 2023
Historique:
received: 27 10 2023
revised: 21 11 2023
accepted: 23 11 2023
medline: 9 12 2023
pubmed: 9 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

Deeper knowledge about the role of the tumor microenvironment (TME) in cancer development and progression has resulted in new strategies such as gene-based cancer immunotherapy. Whereas some approaches focus on the expression of tumoricidal genes within the TME, DNA-based vaccines are intended to be expressed in antigen-presenting cells (e.g., dendritic cells, DCs) in secondary lymphoid organs, which in turn induce anti-tumor T cell responses. Besides effective delivery systems and the requirement of appropriate adjuvants, DNA vaccines themselves need to be optimized regarding efficacy and selectivity. In this work, the concept of DC-focused transcriptional targeting was tested by applying a plasmid encoding for the luciferase reporter gene under the control of a derivative of the human

Identifiants

pubmed: 38069260
pii: ijms242316938
doi: 10.3390/ijms242316938
pmc: PMC10706967
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 1066 B5, B15; SFB1032 B4

Références

J Immunol. 2003 Aug 15;171(4):1825-34
pubmed: 12902483
J Transl Med. 2018 Aug 31;16(1):242
pubmed: 30170620
J Control Release. 2017 Nov 28;266:287-300
pubmed: 28987878
Vaccine. 2022 Apr 6;40(16):2409-2419
pubmed: 35305824
Adv Sci (Weinh). 2023 Nov;10(33):e2303576
pubmed: 37814359
J Pharm Pharmacol. 2006 Jun;58(6):729-37
pubmed: 16734974
Semin Immunopathol. 2017 Feb;39(2):137-152
pubmed: 27888331
Expert Rev Vaccines. 2015 Feb;14(2):221-34
pubmed: 25540984
Cancers (Basel). 2021 Mar 27;13(7):
pubmed: 33801589
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
J Gene Med. 2002 Jan-Feb;4(1):84-91
pubmed: 11828391
ACS Nano. 2018 Oct 23;12(10):9815-9829
pubmed: 30256609
Biomaterials. 2010 Nov;31(32):8172-80
pubmed: 20692033
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12162-7
pubmed: 11593031
Immunol Rev. 2007 Dec;220:151-68
pubmed: 17979845
Nat Rev Cancer. 2019 Oct;19(10):587-602
pubmed: 31492927
Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70
pubmed: 1103152
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Cancers (Basel). 2022 May 31;14(11):
pubmed: 35681718
Life Sci. 2020 Feb 1;242:117241
pubmed: 31891719
J Gene Med. 2000 Mar-Apr;2(2):128-34
pubmed: 10809146
J Pathol. 2011 Jul;224(3):289-300
pubmed: 21618240
Biomaterials. 2013 Jan;34(3):746-55
pubmed: 23107297
J Invest Dermatol. 2000 Oct;115(4):658-63
pubmed: 10998139
J Immunol. 1997 Mar 15;158(6):2723-30
pubmed: 9058806
Pharmaceutics. 2021 May 01;13(5):
pubmed: 34062771
J Allergy Clin Immunol. 2006 Jan;117(1):196-203
pubmed: 16387606
J Control Release. 2018 May 28;278:110-121
pubmed: 29630987
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
Bioconjug Chem. 2008 Jul;19(7):1448-55
pubmed: 18553894
Cancer Lett. 2003 Jul 18;197(1-2):211-7
pubmed: 12880984
Carbohydr Res. 2020 Jan;487:107877
pubmed: 31766009
Hum Gene Ther. 1992 Aug;3(4):399-410
pubmed: 1525212
Bioconjug Chem. 1992 Nov-Dec;3(6):533-9
pubmed: 1463783
Biomaterials. 2015 Jan;38:50-60
pubmed: 25457983
Eur J Pharmacol. 2019 Sep 5;858:172487
pubmed: 31229535
Methods Mol Biol. 2019;1943:83-99
pubmed: 30838611
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
ACS Appl Mater Interfaces. 2021 Mar 31;13(12):14015-14027
pubmed: 33751882
Front Oncol. 2022 May 16;12:878377
pubmed: 35651800
Cancers (Basel). 2022 Jul 06;14(14):
pubmed: 35884359
J Gene Med. 2001 Jul-Aug;3(4):362-72
pubmed: 11529666
Methods Mol Biol. 2021;2197:13-31
pubmed: 32827130
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11
pubmed: 8248244
Int J Biol Sci. 2021 Jul 13;17(11):2944-2956
pubmed: 34345218
J Clin Invest. 2009 Aug;119(8):2231-44
pubmed: 19620771
Cells. 2020 Sep 09;9(9):
pubmed: 32917034
NPJ Vaccines. 2023 Oct 26;8(1):162
pubmed: 37884526
Methods Mol Biol. 2013;940:199-213
pubmed: 23104345
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
pubmed: 7638184
Immunology. 2003 Feb;108(2):177-88
pubmed: 12562326
Adv Healthc Mater. 2022 May;11(9):e2101651
pubmed: 34706166
Sci Transl Med. 2022 Nov 9;14(670):eabo3603
pubmed: 36350990
Hum Gene Ther. 1999 Jul 1;10(10):1659-66
pubmed: 10428211
Cancers (Basel). 2023 Jul 20;15(14):
pubmed: 37509352
Semin Immunol. 2023 Jul;68:101762
pubmed: 37167898
Biomaterials. 2011 Jul;32(21):4936-42
pubmed: 21459440
Proc Natl Acad Sci U S A. 2023 Jun 27;120(26):e2301606120
pubmed: 37339211
Immunology. 2009 Sep;128(1 Suppl):e193-205
pubmed: 18800984
Nat Commun. 2023 Nov 1;14(1):6983
pubmed: 37914693
Virology. 2015 Nov;485:481-91
pubmed: 26363219
Int J Mol Sci. 2022 Jun 11;23(12):
pubmed: 35742987
Cells. 2023 May 29;12(11):
pubmed: 37296625
Nanomedicine (Lond). 2016 Oct;11(20):2647-2662
pubmed: 27628310
Eur J Immunol. 2006 Dec;36(12):3105-17
pubmed: 17111349
Mol Ther. 2017 Jul 5;25(7):1476-1490
pubmed: 28274797
Semin Immunol. 2010 Jun;22(3):155-61
pubmed: 20488726
Immunity. 2010 Oct 29;33(4):492-503
pubmed: 21029960
J Control Release. 2022 Jun;346:110-135
pubmed: 35436520
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146
pubmed: 30953535
Blood. 2003 Jan 15;101(2):649-54
pubmed: 12393580
J Drug Target. 2011 Jun;19(5):315-25
pubmed: 20653408
Signal Transduct Target Ther. 2023 Jul 19;8(1):283
pubmed: 37468460
Curr Opin Immunol. 2020 Aug;65:21-27
pubmed: 32259744
Gene Ther. 2003 Jun;10(12):1035-40
pubmed: 12776161
Theranostics. 2022 May 13;12(9):4081-4109
pubmed: 35673570
Nature. 2023 Jun;618(7963):144-150
pubmed: 37165196
Cell Rep. 2021 Apr 6;35(1):108948
pubmed: 33826900
J Allergy Clin Immunol. 2001 Oct;108(4 Suppl):S99-103
pubmed: 11586274
Oncotarget. 2018 May 22;9(39):25586-25596
pubmed: 29876010
Hum Gene Ther. 1997 Mar 20;8(5):511-2
pubmed: 9095402
FEBS J. 2021 Mar;288(5):1434-1446
pubmed: 32657526

Auteurs

Yanira Zeyn (Y)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Dominika Hobernik (D)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Ulrich Wilk (U)

Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, 81377 Munich, Germany.

Jana Pöhmerer (J)

Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, 81377 Munich, Germany.

Christoph Hieber (C)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Carolina Medina-Montano (C)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Nadine Röhrig (N)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Caroline F Strähle (CF)

Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany.

Andrea K Thoma-Kress (AK)

Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany.

Ernst Wagner (E)

Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, 81377 Munich, Germany.

Matthias Bros (M)

Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, 55131 Mainz, Germany.

Simone Berger (S)

Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, 81377 Munich, Germany.

Classifications MeSH